Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis

Next Previous
Trial Profile

A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arcutis Biotherapeutics

Most Recent Events

  • 28 May 2024 According to an Arcutis Biotherapeutics media release, company announced that Health Canada has accepted for review its Supplement to a New Drug Submission (SNDS) for roflumilast cream 0.15%, for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older based on the results of INTEGUMENT-1, INTEGUMENT-2, INTEGUMENT-OLE, NCT04156191 & NCT03916081 trials.
  • 02 Nov 2020 According to an Arcutis Biotherapeutics media release, data from this study is being presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress (EADV Virtual), Society of Dermatology Physician Assistants (SPDA) Digital 2020 conference, and virtual 2020 Fall Clinical Dermatology Conference.
  • 02 Nov 2020 Results published in the Arcutis Biotherapeutics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top